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Inactivating PTEN mutations are commonly found in prostate cancer, resulting in an increased activation of Akt. In this study, we
investigate the role of PTEN deletion and protein expression in the development of hormone-refractory prostate cancer using
matched hormone-sensitive and hormone-refractory tumours. Fluorescent in situ hybridisation and immunohistochemistry was
carried out to investigate PTEN gene deletion and PTEN protein expression in the transition from hormone-sensitive to hormone-
refractory prostate cancer utilising 68 matched hormone sensitive and hormone-refractory tumour pairs (one before and one after
hormone relapse). Heterogeneous PTEN gene deletion was observed in 23% of hormone sensitive tumours. This increased
significantly to 52% in hormone-refractory tumours (P¼0.044). PTEN protein expression was observed in the membrane, cytoplasm
and the nucleus. In hormone sensitive tumours, low levels of cytoplasmic PTEN was independently associated with shorter time to
relapse compared to high levels of PTEN (P¼0.028, hazard ratio 0.51 (95%CI 0.27–0.93). Loss of PTEN expression in the nucleus
of hormone sensitive tumours was independently associated with disease-specific survival (P¼0.031, hazard ratio 0.52, 95%CI
0.29–0.95). The results from this study demonstrate a role for both cytoplasmic and nuclear PTEN in progression of prostate cancer
to the hormone-refractory state.
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Every year in the Unite Kingdom, almost 32000 cases of prostate
cancer are diagnosed and approximately 10000 die of the disease
(Cancer Research UK web site, 2004). The underlying molecular
mechanisms of prostate cancer initiation and progression are
largely unknown because of extensive tumour heterogeneity.
Patients diagnosed with locally advanced or metastatic prostate
cancer may be treated by androgen ablation therapy, resulting in a
reduction of androgens in the circulation and inhibition of tumour
growth. This treatment is initially successful, but patients tend to
relapse within 18–24 months with disease progression refractory
to therapy (Arnold and Isaacs, 2002). Hormone-refractory prostate
cancer has a poor prognosis, with median survival period reported
to be 24 months. Loss of androgen dependence is often correlated
with the overexpression of antiapoptotic and cell survival
signalling pathways (Johnson and Hamdy, 1998; Karan et al,
2003). Components of these pathways are mutated or abnormally
expressed in many tumour types and mutations of upstream
receptors, such as EGFR, transmit their signals through these
cascades. The loss of tumour suppressor function is also a
common event in the progression to hormone-refractory prostate
cancer and is associated with the gain of oncogenic signalling
(Isaacs and Kainu, 2001). P53, retinablastoma (Rb), NKX3.1 and
phosphatase and tensin homologue deleted on chromosome 10
(PTEN) have all been well documented to have a loss of function
during the progression to hormone-refractory prostate cancer
(Bookstein et al, 1990; Phillips et al, 1994; He et al, 1997; Davies
et al, 1999; McMenamin et al, 1999).
Phosphatase and tensin homologue deleted on chromosome 10
functions as a lipid phosphatase that dephosporylates phosphati-
dylinositol (3, 4 and 5) triphosphate (PIP3), a second messenger
of PI3K at the plasma membrane. PIP3 recruits phosphatidyl-
inositol-dependent kinase-1 (PDK1) and Akt to the membrane.
Here, PDK1 phosphorylates Akt, which leads to its activation.
Akt mediates signals downstream that promote cell survival and
proliferation. Phosphatase and tensin homologue deleted on
chromosome 10 mutants that retain protein tyrosine phosphatase
activity, but lose the ability to dephosphorylate PIP3, are found in
many tumours, indicating that the lipid phosphatase activity
is needed for tumour suppression (Myers et al, 1998). To function
in this manner, PTEN must be located in the cytoplasm; however,
it has recently emerged that there is also a role for PTEN in the
nucleus (Eng, 2003; Chung and Eng, 2005; Lian and Di Cristofano,
2005).
Prostate cancer cell lines that have been cultured from
metastatic sites, such as the lymph nodes (LNCaP) or brain
metastasis (PC3) have highly active PI3K/Akt signalling (Davies
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set al, 1999; Murillo et al, 2001). PTEN mutation has been associated
with 5–27% of localised and 30–60% of metastatic prostate
tumours (Feilotter et al, 1998; Suzuki et al, 1998; Wang et al, 1998).
In addition, loss of PTEN expression is associated with
disease progression and increased risk of recurrence (Gray et al,
1998; McMenamin et al, 1999; Burton et al, 2000; Reiss et al,
2000; Fenci and Woenckhaus, 2002), although substantial hetero-
geneity has been observed between different metastatic sites
within the same patients (Suzuki et al, 1998). Here, we examined
both the deletion of the PTEN gene and expression of PTEN
protein at individual cellular locations in a cohort of matched
hormone-sensitive and hormone-refractory prostate tumours,
with the aim of clarifying the prognostic significance of
PTEN loss in prostate cancer. Using the same cohort, we have
previously demonstrated that the upregulation of Akt activation is
significantly associated with decreased survival, and therefore
PTEN loss is one possible route by which this may occur
(McCall et al, 2008).
MATERIALS AND METHODS
Patients
Sixty-eight patients with matched hormone-sensitive and
hormone-refractory tumour pairs were retrospectively selected
for the analysis. All tumours had patient identification removed,
and the clinical information database was anonymised. Ethical
approval was obtained from the Multicentre Research Ethics
Committee for Scotland (MREC/01/0/36) and fron the Local
Research and Ethical Committees. Patients were only selected
for analysis if they initially responded to hormone treatment
(in the form of subcapsular bilateral orchidectomy or maximum
androgen blockade), but subsequently relapsed (two consecutive
rises in PSA greater than 10%) and had a pre- and post-hormone
relapse tissue sample available for analysis. Hormone-refractory
prostate cancer specimens were obtained by TURP, when patients
required further surgical procedures to treat clinical symptoms
such as bladder outflow obstruction. All these samples were
obtained with 8 weeks of biochemical relapse being diagnosed
(two consecutive rises in PSA greater than 10%). Phosphorylated
Akt expression is already available for this patient cohort
(McCall et al, 2008).
Fluorescent in situ hybridisation
Fluorescent in situ hybridisation (FISH) was performed on 5mm,
archival formalin fixed, paraffin-embedded prostate tumour tissue
arrays. Slides were incubated for 1h at 561C, dewaxed and
rehydrated through graded alcohols. Tissue was then pretreated
using histology FISH accessory kit (Dako A/S, Glostrup,
Denmark). In brief, slides were rinsed twice in wash buffer and
then incubated for 10min in pretreatment buffer at 951C, followed
by a 3-min incubation at room temperature in wash buffer.
Slides were then incubated in pepsin for 26min at 251C, followed
by a 3-min incubation at room temperature in wash buffer.
Dako A/S provided PTEN probe; 10ml of probe was applied to
each slide and incubated at 821C for 22min followed by an
overnight incubation at 451C. Slides were then washed in stringent
wash buffer for 10min at 651C, followed by two 3-min washes in
wash buffer. Slides were dehydrated through graded alcohols,
mounted in DAPI Vectashield (Vector Laboratories, CA, USA) and
viewed using a Leica DMLB microscope at  400 magnification
(Figure 1A). Fluorescent in situ hybridisation was scored by
two independent observers; the number of signals for each
chromosome (green) and gene (red) were counted in 20 non-
overlapping nuclei. The gene-to-chromosome ratio was then
calculated. PTEN loss was classified as a gene-to-chromosome
ratio of p0.8 (Watters et al, 1998).
Immunohistochemistry
Tumour expression of PTEN was determined in archival formalin
fixed, paraffin-embedded prostate tissue sections (5mm) by IHC.
Sections were dewaxed in xylene and rehydrated through graded
alcohols before blocking endogenous peroxidase in 3% hydrogen
peroxide. Antigen retrieval was performed by heating tissue
sections under pressure in citrate buffer (pH 6) for 5min. Sections
were blocked using 1.5% horse serum; PTEN antibody (Cell
Signalling Technology) was used at 1mgml
 1, and incubated
overnight at 41C. Staining was developed using Envision plus kit
(Dako A/S). Nuclei were counterstained with haematoxylin before
mounting. An example of the staining is shown in Figure 1
(Figure 1B). A positive and negative control slide was included in
each IHC run; negative controls were incubated with an isotype
matched control antibody at a concentration of 1mgml
 1. Cell
pellets known to express or not express PTEN were also included
in each run. Antibody specificity was confirmed by western blot
analysis (Figure 1C).
Staining was scored blind by two independent observers using
a weighted histoscore method (Kirkegaard et al, 2006) also
known as the H-score system (McCarty et al, 1986). Histoscores
were calculated from the sum of (1  the percentage of cells
staining weakly positive) þ (2  the percentage of cells staining
moderately positive) þ (3  the percentage of cells staining
strongly positive) with a maximum histoscore of 300. The
interclass correlation coefficient (ICCC) between each observer
was confirmed to measure consistency. The ICCC value was 40.7,
which is classed as excellent as; an ICCC of 1 indicates identical
score (Kirkegaard et al, 2006). The mean of the two observer’s
histoscores was used for the analysis. Changes in protein-
expression staining between hormone-sensitive and hormone-
refractory cases were defined as an increase or decrease with the
95% confidence interval for the difference in the interobserver
variation (ie, the mean difference between the histoscore that each
observer assigns for protein expression ±2 s.d.; Edwards et al,
2003).
All statistical analyses were performed using the SPSS version
9.0 for Windows. Protein expression data were not normally
distributed and is given as median and interquartile ranges.
Wilcoxon signed-rank tests were used to compare protein
expression between hormone-sensitive and hormone-refractory
prostate cancer tumours. Survival analysis was conducted using
the Kaplan–Meier method, and curves were compared with the
log-rank test. Multivariate survival analysis and hazard ratios
(HRs) were calculated using Cox regression analysis. A value of
Po0.05 was considered statistically significant.
RESULTS
Patients in this cohort were diagnosed with locally advanced (50)
or metastatic prostate cancer (18), and subsequently received
surgery and androgen deprivation therapy (26 subcapsular
bilateral orchidectomy, 44 GnRH analogue and two had both). In
all, 45 of the 68 patients also received an antiandrogen therapy and
this included all those who received GnRH analogues. At initial
diagnosis, the median age was 70 (66–74) years and 26% of
patients had metastatic disease. The median time to biochemical
relapse was 2.32 (1.48–4.00) years and the percentage of patients
with metastatic disease had increased to 57%. Sixty-one patients
(89.7%) died during follow-up, and median survival for these
patients was 4.34 (2.94–6.63) years. Seven patients were alive at
the last follow-up; the median time of follow-up for all 68 patients
was 4.34 (2.86–6.74) years.
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to death from biochemical relapse and disease-specific
survival
When serum PSA level, age, metastasis and Gleason grade at
diagnosis were analysed for this patient, cohort using the Kaplan–
Meier log-rank method, PSA at diagnosis (P¼0.036) and Gleason
score at diagnosis (P¼0.010) were associated with shorter time to
biochemical relapse.
Death at the time of biochemical relapse was associated with
PSA level at relapse (P¼0.016). Overall survival was associated
with the presence of metastases at relapse (P¼0.0019) and Gleason
score at diagnosis (P¼0.049).
Fluorescent in situ hybridisation
PTEN deletions Of the 68 prostate carcinomas investigated,
PTEN/chromosome 10 ratio was successfully evaluated in 57
(84%) cases. The remaining cases were excluded from the study
because of insufficient tumour material in the cores. The mean
PTEN/chromosome 10 ratio for the hormone-sensitive and
hormone-refractory tumours was 0.98 (range: 0.71–1.11) and
0.92 (range: 0.39–2.16), respectively. Gene deletion as identified by
FISH was observed in 23% of hormone-sensitive tumours; this
increased significantly to 52% in hormone-refractory tumours
(P¼0.044). Loss of one copy of PTEN was commonly observed,
and this was heterogeneous in nature, being frequently observed in
only one area of tumour. Loss of PTEN was correlated with
prostate cancer progression; however, no correlation was observed
between the loss of PTEN and Gleason score at diagnosis, loss of
PTEN and presence of metastasis at diagnosis or the loss of PTEN
and PSA at diagnosis. When loss of PTEN was correlated with
survival, a trend between the loss of PTEN and poorer disease-
specific survival was noted (P¼0.086); this was not independently
significant by Cox regression analysis.
Gene number and chromosomal aneusomy In the informative
cases, the mean PTEN gene copy number per counted cancer
cell for the hormone-sensitive and hormone-refractory cases was
1.90 (range: 1.4–2.5) and 1.71 (range: 0.80–3.45) respectively.
When assessing the frequency of chromosome aneusomy, the
mean chromosomal copy number of chromosome 10 for the
hormone-sensitive and hormone-refractory tumours was 1.93
(range: 1.75–2.25) and 1.87 (range: 1.60–2.05), respectively.
Normal range for chromosomal copy number is 1.35–2.01, in this
cohort, none of the hormone-sensitive or hormone-refractory
tumours appeared to have lost chromosome 10 as 0% had
chromosome 10 copy number per counted cancer cell of less than
1.35, which is the lower limit of the normal range. In contrast, 12%
of the hormone-sensitive tumours and 21% of the hormone-
refractory tumours had chromosome 10 copy numbers per
counted cancer cell higher than that of the normal range. It was
noted that this was a different subgroup of patients exhibiting the
loss of PTEN gene.
Immunohistochemistry
Membrane, cytoplasmic and nuclear PTEN expression was
observed in prostate tissue. In the hormone-sensitive tumours,
membrane and nuclear expression were less frequently observed
than cytoplasmic expression; 41 and 46% of patients, respectively,
had membrane and nuclear expression compared with
95% expressing PTEN in the cytoplasm. The interquartile range
of expression for each location is shown in Table 1. This
rate of expression did not significantly change in the hormone-
refractory tissue. When median protein expression levels in the
hormone-sensitive and hormone-refractory tissue were
compared, no statistically significant change was observed
at any cellular location. Loss of PTEN expression was
heterogeneous.
LNCap
cell 
lystates
DU 145
cell 
lysates
Figure 1 (A) shows an example of fluorescent in situ hybridisation for chromosome 10 (red signal) and PTEN (green signal). (B) Shows an example of
immunohistochemistry for PTEN protein expression; in hormone-sensitive prostate cancer, both cytoplasmic expression and nuclear expression are present.
(C) Western blot analysis for PTEN protein to confirm antibody specificity. LNCaP cells do not express PTEN protein, whereas DU145 cells do express
PTEN protein. Lane 1, hormone-sensitive LNCaP cell lysates; lane 2, hormone-refractory LNCaP cell lysates; lane 3, DU145 cell lysates.
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sHormone-sensitive tumours
To determine whether protein expression was linked to time to
biochemical relapse, Kaplan–Meier graphs were plotted for the
hormone-sensitive tumours expressing low levels of protein
(omedian histoscore) vs high levels of protein (4median
histoscore), and compared using the log-rank test. The patients
whose tumours expressed low levels of PTEN in the cytoplasm
were shown to have relapsed significantly earlier than those
patients whose tumours expressed high levels of PTEN in the
cytoplasm (Figure 2A, P¼0.027). Cox regression analysis indicates
that cytoplasmic PTEN expression is independent of known
clinical prognostic factors (P¼0.028, HR 0.51 (95% CI 0.27–
0.93). It was noted, however, that the Kaplan–Meier curves did not
separate until approximately 2.5 years after diagnosis. Therefore,
PTEN loss appeared to be influencing relapse in those patients who
took more than 30 months to relapse. If patients who relapsed
within 30 months were excluded from the analysis, the median
time to relapse for those with low PTEN expression was 3.9 (IQR
2.98–4.92) years compared to 5.6 (4.36–6.84) years for those with
high PTEN expression (P¼0.0035; Figure 2B). In addition, those
patients with high levels of cytoplasmic PTEN expression in their
hormone-sensitive tumours were observed to have longer median
overall survival (6.1 years (IQR 2.8–9.4)) compared to those with
low PTEN expression (4.4 years (IQR 3.3–5.4)), although this did
not reach significance (P¼0.072; Figure 2C). Again the curves first
separate approximately 30 months after diagnosis.
Expression of phosphorylated Akt at serine 473 (activated Akt)
for this cohort of patients had already been established in a
previous study (McCall et al, 2008). Levels of phosphorylated Akt
expression in tumours that expressed low levels of PTEN was
higher compared to tumours that expressed high levels of PTEN
(P¼0.047).
The median for both PTEN membrane and nuclear expression
in the hormone-sensitive tumours was 0; therefore patients were
divided into those patients whose tumours did not express PTEN
Table 1 Histoscore variation and comparison of staining intensity for hormone-sensitive and hormone-refractory tumours
HSPC (IQR) HRPC (IQR) P-value ICCC Fallers (%) Risers (%)
PTEN membrane 0–67.5 0–40 0.086 0.84 33 15
PTEN cytoplasm 80–150 80–107 0.104 0.90 33 23
PTEN nucleus 0–50 0–80 0.588 0.82 28 25
The interquartile range (IQR) for hormone-sensitive tumours (HSPC) and hormone-refractory tumours (HRPC) are shown. The P-value was compared using a Wilcoxon signed-
rank test. The interclass correlation coefficient (ICCC), which measures the consistency among observers for each protein, is consistently higher than 0.7, which is classed as
excellent. The percentage of tumours that was defined as having a rise or fall in protein expression (calculated using the number of histoscore units that is defined as a change in
expression) is also shown.
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Figure 2 (A) Shows a Kaplan–Meier plot for high (above the median, solid line) and low (below the median, dotted line) PTEN cytoplasmic expression
and time to biochemical relapse (P¼0.027). (B) Shows a Kaplan–Meier plot for high (above the median, solid line) and low (below the median, dotted line)
PTEN cytoplasmic expression for patients that took longer than 30 months to relapse (P¼0.0035). (C) shows a Kaplan–Meier plot for high (above the
median, solid line) and low (below the median, dotted line) PTEN cytoplasmic expression and disease-specific survival (labelled overall survival; P¼0.072).
(D) Shows a Kaplan–Meier plot for patients with tumours that have membrane PTEN expression (solid line) compared to patients whose tumours do not
have nuclear PTEN expression (dotted line) and disease-specific survival (labelled overall survival; P¼0.002). (E) Shows a Kaplan–Meier plot for patients
with tumours that have nuclear PTEN expression (dotted line) compared to patients whose tumours do not have nuclear PTEN expression (solid line) and
time to biochemical relapse (P¼0.078). (F) Shows a Kaplan–Meier plot for patients with tumours that have nuclear PTEN expression (solid line) compared
to patients whose tumours do not have nuclear PTEN expression (dotted line) and disease-specific survival (labelled overall survival; P¼0.003).
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membrane expression in their hormone-sensitive tumour had
significantly longer overall survival than those patients without
(Figure 2D, P¼0.002). The median time to relapse for patients
whose tumours did not express PTEN in the membrane was 3.8
years (IQR 2.7–4.85) compared to 6.5 (IQR 5.8–7.2) years for
patients with membrane expression.
Patients with no nuclear PTEN expression relapsed earlier than
those with nuclear PTEN expression, although this did not reach
significance (Figure 2E, P¼0.078). PTEN nuclear expression was
associated with overall survival, those patients whose tumours had
no nuclear PTEN expression had a significantly shorter overall
survival compared to those patients with PTEN nuclear expression
(Figure 2F, P¼0.003). Median overall survival was 3.4 years
(IQR 2.6–4.2) compared to 6.5 years (IQR 5.1–7.8) that confers a
survival advantage of 3 years for those patients whose tumours
express nuclear PTEN. Nuclear PTEN expression was demon-
strated to be an independent prognostic marker by Cox regression
analysis, when compared with known clinical prognostic para-
meters (P¼0.031, HR 0.52 (95% CI 0.29–0.95).
As observed with membrane expression, phosphorylated Akt
expression was lower in the nucleus of tumours with high levels of
nuclear PTEN than those with low levels, but this did not reach
significance (P¼0.132). In contrast, PTEN membrane expression
correlated strongly with nuclear PTEN expression (Po0.001,
RS 0.66).
Hormone-refractory tumours
Phosphatase and tensin homologue deleted on chromosome 10
expression levels in the hormone-refractory tumours were not
associated with time to death from relapse, disease-specific death
from relapse or with the presence of metastasis.
DISCUSSION
The PTEN tumour suppressor has emerged as a critical regulator
of cellular processes, which is frequently mutated or deleted in a
number of human cancers, including prostate cancer. Fluorescent
in situ hybridisation and IHC have demonstrated that a significant
proportion of patients have heterogeneous PTEN deletion and
loss of PTEN protein expression, which is, associated with clinical
outcome measures.
The frequency and mode of PTEN inactivation reported at
various stages of clinical prostate cancer are variable (Verhagen
et al, 2006). In this study, we investigated the level of PTEN loss by
FISH in matched hormone-sensitive and hormone-refractory
tumours. Loss was noted in 23% hormone-sensitive tumours
compared with 52% hormone-refractory tumours; these rates are
similar to those previously reported by FISH analysis (Verhagen
et al, 2006). Fluorescent in situ hybridisation depending on the
region that the probe binds to does not always detect small
deletions, and in the case of our study, the probe covers the whole
of the PTEN gene. Therefore, in this study, loss of the whole gene is
being measured. It was observed that very few tumours had
homogeneous PTEN deletion and complete loss of PTEN expres-
sion (2%), but almost all have heterogeneous loss of expression;
this is consistent with previous reports (Verhagen et al, 2006). In
this study, PTEN loss does not correlate with PTEN gene deletion,
although all tumours with PTEN deletion have low PTEN
expression. An explanation for low PTEN expression in tumours
that appear not to have PTEN deletion is the hypermethylation of
the PTEN promoter region. Evidence for promoter hypermethyla-
tion has been reported in prostate cancer xenografts (Whang et al,
1998). Although the mechanism of PTEN inactivation is currently
controversial and possibly because of different mechanisms in
different tumours, it is widely accepted that PTEN loss is one of the
most common events associated with prostate cancer (Majumder
and Sellers, 2005). Consistent with these findings, this study
observed a higher rate of PTEN deletion by FISH in hormone-
refractory compared to hormone sensitive tumours, suggesting
that PTEN loss is associated with tumour progression. Although
this was not significantly associated with clinical outcome
measures, a trend was observed demonstrating that those patients
with PTEN loss had shorter overall survival. If the FISH studies
were expanded to a larger data set, these results might have
reached significance.
As predicted, loss or low cytoplasmic PTEN expression was
independently associated with time to relapse and linked with
increased Akt activation. Surprisingly, however, this was observed
to be a late event with curves separating 30 months following
diagnosis, suggesting that other factors, such as PI3K expression,
may also contribute to Akt activation and disease progression.
Cytoplasmic PTEN expression was only weakly associated with
overall survival, and this did not reach significance in this study.
However, in addition to cytoplasmic PTEN expression, nuclear
PTEN expression was also observed. Unlike cytoplasmic PTEN
expression, loss of nuclear PTEN expression was weakly associated
with time to relapse, and this did not reach significance. Nuclear
PTEN expression was, however, independently strongly associated
with overall survival, and the curves on the Kaplan–Meier plot
begun to separate almost immediately after diagnosis. These
results in combination with the lack of correlation with Akt
activation suggest that the role of PTEN in the nucleus is
independent of cytoplasmic PTEN. It is now recognised that
PTEN has a function in the nucleus, and reports of PTEN nuclear
localisation have begun to multiply over the past few years in
tumour and non-tumour cells (Gimm et al, 2000). Chung et al
(2005) have demonstrated that PTEN has dual nuclear localisation
signal-like sequences that mediate nuclear import, and have shown
that nuclear PTEN is required for PTEN-mediated cell-cycle arrest
and growth inhibition through the downregulation of cyclin D1.
Reports from the literature also suggest that PTEN localises to the
nucleus during the G0-G1 phase of cell cycle and mediates growth
suppression through the inhibition of MAP kinase phosphoryla-
tion independent of Akt activation (Chung and Eng, 2005; Chung
et al, 2006). Results from our study support the hypothesis that
PTEN has a distinct function in the nucleus independent of its
cytoplasmic role.
However, it is a possibility that nuclear PTEN is simply a
surrogate marker of PTEN activation as in vitro studies
demonstrate that following phosphorylation, PTEN is released
from the membrane-bound scaffolding proteins and enters the
nucleus. In support of this, we report a correlation between
membrane and nuclear PTEN expression (Po0.001, Rs 0.66), and
PTEN membrane expression is also linked to survival. However, in
contrast to cytoplasmic PTEN expression, no correlations were
observed between nuclear PTEN expression and Akt activation;
therefore, the evidence to support nuclear PTEN as a surrogate
marker of PTEN cytoplasmic activation is not convincing in this
study.
In summary, the rate of loss of PTEN as measured by FISH
increased with disease progression, and a trend was noted between
PTEN loss and poorer disease-specific survival, suggesting that this
arm of the study should be expanded to larger cohort. In addition,
both cytoplasmic and nuclear PTEN are independently associated
with good outcome measures in hormone-sensitive prostate
cancer, but appear to have independent roles.
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